Pharma Pioneer

Preliminary ARTACUS Trial Data on RP1 Solo Treatment for Skin Cancer in Transplant Patients Showcased at AACR 2024

17 May 2024
3 min read

Replimune Group, a biotech firm specializing in oncolytic immunotherapies, has reported promising interim findings from the ARTACUS Phase 1/2 clinical trial. The study, which focuses on the use of RP1 monotherapy for skin cancer treatment in transplant patients, was detailed at the AACR 2024 Annual Meeting by Dr. Michael R. Midgen from the University of Texas MD Anderson Cancer Center. 

RP1 monotherapy, administered up to 25 times, demonstrated an overall response rate of 34.8% among 23 evaluable patients. This included five complete responses and three partial responses, with most responses still ongoing as of September 18, 2023. The patient group comprised 20 with cutaneous squamous cell carcinoma and three with merkel cell carcinoma

Notably, a CSCC patient also experienced a complete response in a new primary basal cell carcinoma that emerged after the baseline. The treatment showed no signs of allograft rejection and was well-tolerated, with a safety profile akin to that of non-immunocompromised patients with advanced skin cancers. Post-treatment biomarker analysis indicated an increase in CD+8 T cells and PD-L1 expression, pointing to immune system activation. Dr. Sushil Patel, CEO of Replimune, highlighted the higher risk of skin cancer in organ transplant recipients and the limited treatment options available due to systemic immunotherapy contraindications. 

The data suggest that RP1 monotherapy could be a safe and effective alternative, with a nearly 35% overall response rate and sustained benefits. The ARTACUS trial is a multicenter, open-label study assessing the safety and tumor-reducing capabilities of RP1 monotherapy in patients with locally advanced or metastatic cutaneous malignancies who have undergone organ or hematopoietic cell transplantation and are on chronic immunosuppressive treatment. The trial is actively recruiting participants. RP1, Replimune's lead candidate, is a modified herpes simplex virus designed to enhance tumor destruction and stimulate a systemic anti-tumor immune response. Replimune, founded in 2015 and based in Woburn, MA, aims to revolutionize cancer treatment with its innovative oncolytic immunotherapy portfolio. 

The company's RPx platform is engineered for potent immunogenic cell death and systemic immune response induction, with potential synergies with various cancer treatments. The press release includes forward-looking statements regarding the clinical trial design, product candidate development, and potential regulatory approvals, which are subject to risks and uncertainties that could significantly affect actual outcomes. Replimune's actual results may vary materially from the forward-looking statements due to factors such as operating history limitations, clinical trial results, regulatory changes, competitive challenges, and global health issues like the coronavirus pandemic. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Three-Year Data Shows Persistent Immune Response and Reduced Tumor Recurrence in Resected Pancreatic Cancer Patients Using mRNA Immunotherapy
Pharma Pioneer
4 min read
Three-Year Data Shows Persistent Immune Response and Reduced Tumor Recurrence in Resected Pancreatic Cancer Patients Using mRNA Immunotherapy
17 May 2024
The three-year outcomes from a Phase 1 study of a personalized mRNA cancer vaccine, autogene cevumeran (BNT122, RO7198457), have demonstrated sustained polyspecific T cell reactions and a reduction in tumor recurrence in patients.
Read →
Promising Linvoseltamab Phase 1/2 Results at AACR Showcase Progressive Response in Relapsed/Refractory Multiple Myeloma Patients
Pharma Pioneer
3 min read
Promising Linvoseltamab Phase 1/2 Results at AACR Showcase Progressive Response in Relapsed/Refractory Multiple Myeloma Patients
17 May 2024
Regeneron Pharmaceuticals has reported encouraging results from their Phase 1/2 clinical trial of linvoseltamab.
Read →
Vincerx Showcases Favorable Initial Phase 1 Findings for VIP236 and Pipeline Developments at AACR's 2024 Annual Gathering
Pharma Pioneer
2 min read
Vincerx Showcases Favorable Initial Phase 1 Findings for VIP236 and Pipeline Developments at AACR's 2024 Annual Gathering
16 May 2024
Vincerx Pharma, a biopharmaceutical firm, has reported encouraging preliminary results from the Phase 1 clinical trial of its drug candidate VIP236, which targets metastatic solid tumors.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - May 16
Pharma Frontiers
11 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - May 16
16 May 2024
May 16th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.